Everolimus-Eluting Platinum Chromium Coronary Stent System

Freedom From Long-term Polymer Exposure

Professors Ian Meredith, Adrian Banning and Tan Huay Cheem provide their commentary about the SYNERGY stent platform, and the recently reported data from the EVOLVE Trial 4-Year and EVOLVE II Trial Diabetes Substudy 12 month presentations.  In addition, they also provide their analysis of the increasing evidence of how the SYNERGY stent may lead to optimal healing and reducing the risk of neoathersclerosis.


Synchronous Drug Elution and Polymer Absorption

SYNERGY Stent offers peace of mind knowing the polymer is fully absorbed between three and four months.2

Exceptional Safety and Performance

Long-term data shows promising results with ZERO ARC definite/probable stent thrombosis and exceptionally low target lesion revascularization out to four years.
Four-Year Results: 0% ARC Definite/Probable ST and 1.1% TLR at Four Years1
Three-Year Results
One NQWMI in the SYNERGY group was periprocedural. The remaining 2 NQWMI in the SYNERGY arm were considered unrelated to the study device: one at day 347 due to anemia and a major GI bleed, and one at day 364 subsequent to respiratory failure in a patient with severe COPD – enzymes were checked indicating that a NQWMI had occurred. The one death was of an unknown cause at day 472 and adjudicated as a Cardiac Death. Safety Population. (PROMUS Element N = 98; SYNERGY N = 92) All p-values are >0.05.

EVOLVE II Diabetes Substudy

12-Month Clinical Results

EVOLVE II  DM Clinical Trial. Presented by Stephan Windecker, MD at PCR 2015

^Cutlip et al, Circulation. 2007; 115(17):2344;
* Spontaneous MI was defined as the rise and/or fall of cardiac biomarkers with ≥1 value >99th percentile of the upper reference limit (URL) with ≥1 of the following: symptoms of ischemia, ECG changes, and or evidence of loss of myocardium. Peri-PCI MI was defined by any of the following: i) CK-MB >3X URL within 48 hours, ii) new pathological Q waves, iii) autopsy evidence.  All ST were definite.